EP2091969A4 - POLYPEPTIDES HAVING REDUCED INCREASED ANTIINFLAMMATORY AND CYTOTOXIC PROPERTIES AND RELATED METHODS - Google Patents

POLYPEPTIDES HAVING REDUCED INCREASED ANTIINFLAMMATORY AND CYTOTOXIC PROPERTIES AND RELATED METHODS

Info

Publication number
EP2091969A4
EP2091969A4 EP07812601A EP07812601A EP2091969A4 EP 2091969 A4 EP2091969 A4 EP 2091969A4 EP 07812601 A EP07812601 A EP 07812601A EP 07812601 A EP07812601 A EP 07812601A EP 2091969 A4 EP2091969 A4 EP 2091969A4
Authority
EP
European Patent Office
Prior art keywords
polypeptides
related methods
cytotoxic properties
reduced increased
antiinflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07812601A
Other languages
German (de)
French (fr)
Other versions
EP2091969A2 (en
Inventor
Falk Nimmerjahn
Yoshikatsu Kaneko
Jeffrey V Ravetch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/041791 external-priority patent/WO2007055916A2/en
Priority claimed from PCT/US2007/008396 external-priority patent/WO2007117505A2/en
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of EP2091969A2 publication Critical patent/EP2091969A2/en
Publication of EP2091969A4 publication Critical patent/EP2091969A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP07812601A 2006-10-27 2007-07-03 POLYPEPTIDES HAVING REDUCED INCREASED ANTIINFLAMMATORY AND CYTOTOXIC PROPERTIES AND RELATED METHODS Ceased EP2091969A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2006/041791 WO2007055916A2 (en) 2005-11-07 2006-10-27 Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
PCT/US2007/008396 WO2007117505A2 (en) 2006-04-05 2007-04-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PCT/US2007/072771 WO2008057634A2 (en) 2006-10-26 2007-07-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (2)

Publication Number Publication Date
EP2091969A2 EP2091969A2 (en) 2009-08-26
EP2091969A4 true EP2091969A4 (en) 2010-05-12

Family

ID=39367532

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07812601A Ceased EP2091969A4 (en) 2006-10-27 2007-07-03 POLYPEPTIDES HAVING REDUCED INCREASED ANTIINFLAMMATORY AND CYTOTOXIC PROPERTIES AND RELATED METHODS

Country Status (3)

Country Link
EP (1) EP2091969A4 (en)
AU (1) AU2007317755A1 (en)
WO (1) WO2008057634A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
MX2008012843A (en) 2006-04-05 2009-01-19 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods.
BRPI0910091A2 (en) 2008-03-27 2017-05-30 Novozymes As process to produce a fermentation product
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
EP2233502A1 (en) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2427497B1 (en) 2009-05-07 2016-12-07 Stallergenes Use of igg1 immunoglobulins and/or ligands of the cd32 receptor for treating inflammatory diseases and incidents via the mucosa
CA2766839A1 (en) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Enzymatic antibody processing
EP2566889A1 (en) 2010-05-07 2013-03-13 CSL Behring AG Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
WO2012012590A2 (en) 2010-07-23 2012-01-26 Novozymes A/S Processes for producing fermentation products
KR101584416B1 (en) 2010-10-05 2016-01-13 에프. 호프만-라 로슈 아게 Antibodies against human tweak and uses thereof
WO2012068134A1 (en) * 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
AR085302A1 (en) 2011-02-24 2013-09-18 Sanofi Sa METHOD OF PRODUCTION OF STIRATED ANTIBODIES
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9650433B2 (en) 2011-05-20 2017-05-16 Momenta Pharmaceuticals, Inc. Modified glycoproteins
JP5854535B2 (en) 2011-10-05 2016-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Methods for the production of antibody G1 glycoforms
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013163297A1 (en) 2012-04-25 2013-10-31 Momenta Pharmaceuticals, Inc. Modified glycoproteins
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP7774283B2 (en) 2017-12-19 2025-11-21 ザ ロックフェラー ユニバーシティー Human IgG Fc region variants with improved effector functions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
WO2000063403A2 (en) * 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
WO2004058944A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2007005786A2 (en) * 2005-06-30 2007-01-11 Centocor, Inc. Methods and compositions with enhanced therapeutic activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
WO2000063403A2 (en) * 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
WO2004058944A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2007005786A2 (en) * 2005-06-30 2007-01-11 Centocor, Inc. Methods and compositions with enhanced therapeutic activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DALZIEL MARTIN ET AL: "Lectin analysis of human immunoglobulin G N-glycan sialylation", GLYCOCONJUGATE JOURNAL, vol. 16, no. 12, December 1999 (1999-12-01), pages 801 - 807, XP002575135, ISSN: 0282-0080 *
JASSAL R ET AL: "Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 AUG 2001, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 243 - 249, XP002574380, ISSN: 0006-291X *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075 *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1129594 *
NIMMERJAHN FALK ET AL: "The antiinflammatory activity of IgG: the intravenous IgG paradox", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, no. 1, January 2007 (2007-01-01), pages 11 - 15, XP002575137, ISSN: 0022-1007 *
RAJU T SHANTHA ET AL: "Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 40, no. 30, 31 July 2001 (2001-07-31), pages 8868 - 8876, XP002461128, ISSN: 0006-2960 *
SCALLON ET AL: "Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 7, November 2006 (2006-11-01), pages 1524 - 1534, XP005792683, ISSN: 0161-5890 *
See also references of WO2008057634A2 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED .ALPHA.-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 263, no. 10, 5 April 1988 (1988-04-05), pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED ALPHA-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 10, 1988, pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP2091969A2 (en) 2009-08-26
WO2008057634A2 (en) 2008-05-15
AU2007317755A1 (en) 2008-05-15
WO2008057634A3 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
EP2091969A4 (en) POLYPEPTIDES HAVING REDUCED INCREASED ANTIINFLAMMATORY AND CYTOTOXIC PROPERTIES AND RELATED METHODS
BRPI0719369A2 (en) PROSTHESIS HOLDER AND APPLICATIONS
GB2446843B (en) Amplifier circuit and methods of operation thereof
EP1967207A4 (en) INHIBITOR OF INDUCTION OF CYTOTOXIC T CELLS
EP2010566A4 (en) POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND REDUCED CYTOTOXIC PROPERTIES, AND CORRESPONDING METHODS
IL196799A0 (en) Fused heterocyclic derivative and use thereof
DK3207941T6 (en) PROCEDURES AND COMPOSITIONS BASED ON DIPHTHERITOXIN-INTERLEUKIN-3 CONJUGATES
EP1987184A4 (en) CARBON / CARBON PARTS AND METHODS OF MAKING SAME
EP2007877A4 (en) METHODS FOR COMPACT AGGREGATION OF DERMIC CELLS
EP2038947A4 (en) Fluid enclosure and methods related thereto
DE602007010272D1 (en) PARKING AIDS AND PARKING PROCEDURE
DK2865361T3 (en) TEA REPLACEMENTS AND RELATED PROCEDURES
EP2197380A4 (en) Electrosurgical instrument and method
GB0904193D0 (en) Powered wheelchair having an articulating beam and related methods of use
DK2069312T3 (en) pyridazinone
DK3263589T3 (en) PEPTIDE SEQUENCES AND COMPOSITIONS
IL192581A0 (en) Rage fusion proteins and methods of use
TWI349426B (en) Bias circuit and power amplifier
EP1972256A4 (en) ENDOSCOPE AND ROTARY SELF-ENGINE ENDOSCOPE
EP1991565A4 (en) SHIGA TOXOID CHIMERIC PROTEINS
IL197543A0 (en) Molecular switches and methods for their use
DE602007006573D1 (en) Magnetic particles and manufacturing methods therefor
ATE537183T1 (en) HIV FUSION INHIBITOR PEPTIDES WITH IMPROVED BIOLOGICAL PROPERTIES
DK2099304T3 (en) CARBORANYL PORPHYRINES AND APPLICATIONS THEREOF
DK2023668T3 (en) HEARING WITH VISUALIZED PSYCHOACUSTIC VARIABLES AND SIMILAR PROCEDURE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAVETCH, JEFFREY V.

Inventor name: NIMMERJAHN, FALK

Inventor name: KANEKO, YOSHIKATSU

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE ROCKEFELLER UNIVERSITY

A4 Supplementary search report drawn up and despatched

Effective date: 20100414

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135408

Country of ref document: HK

17Q First examination report despatched

Effective date: 20100719

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135408

Country of ref document: HK